抗CD20单克隆抗体药物的研发进展  

Research and Development Progress of Anti-CD20 Monoclonal Antibody Drugs

作　　者：郑淑贞 周逢云 代虎 朱建伟 ZHENG Shuzhen;ZHOU Fengyun;DAI Hu;ZHU Jianwei(Engineering Research Center of Cell and Therapeutic Antibody,Ministry of Education,School of Pharmacy,Shanghai Jiao Tong University,Shanghai 200240;Shanghai Henlius Biopharmaceuticals Co.,Ltd.,Shanghai 200233)

机构地区：[1]上海交通大学药学院,细胞工程及抗体药物教育部工程研究中心,上海200240 [2]上海复宏汉霖生物制药有限公司,上海200233

出　　处：《中国医药工业杂志》2021年第11期1452-1459,共8页Chinese Journal of Pharmaceuticals

摘　　要：非霍奇金淋巴瘤(NHL)是一种十分常见的造血系统恶性肿瘤。大量的基础研究证实了B细胞分化抗原20(CD20)是治疗淋巴瘤的重要靶点。抗CD20单克隆抗体药物不仅可以治疗NHL,还为多发性硬化、风湿性关节炎等疾病提供了更多治疗机会。本研究从CD20抗原靶点、抗CD20单克隆抗体药物作用机制以及抗CD20单克隆抗体药物的发展等方面进行了综述,为抗CD20单克隆抗体药物的发展提供参考。Non-Hodgkin lymphoma(NHL)is a common malignant tumor of the hematopoietic system.A large number of basic studies have confirmed that CD20 is an important target for the treatment of lymphoma.Anti-CD20 monoclonal antibody drugs can not only treat NHL,but also provide more treatment opportunities for multiple sclerosis,rheumatoid arthritis and other diseases.The CD20 antigen targets,action mechanism of anti-CD20 monoclonal antibody drugs,and the development of anti-CD20 monoclonal antibody drugs are reviewed in this study,which provide a reference for the development of anti-CD20 monoclonal antibody drugs.

关 键 词：非霍奇金淋巴瘤 CD20 单克隆抗体 

分 类 号：R979.1[医药卫生—药品] R973[医药卫生—药学]